Pre-made Erenumab benchmark antibody ( Whole mAb, anti-CALCRL/CGRPR therapeutic antibody, Anti-CRLR/LMPHM8 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Erenumab biosimilar, Whole mAb, Anti-CALCRL/CGRPR Antibody: Anti-CRLR/LMPHM8 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Erenumab, sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine.
| Products Name (INN Index) | Pre-Made Erenumab biosimilar, Whole mAb, Anti-CALCRL/CGRPR Antibody: Anti-CRLR/LMPHM8 therapeutic antibody |
|---|---|
| INN Name | Erenumab |
| Target | CALCRL |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | 6umh:HL/6umi:HL/6umj:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Amgen,Novartis |
| Conditions Approved | Migraine |
| Conditions Active | NA |
| Conditions Discontinued | Hot flushes |
| Development Tech | Abgenix XenoMouse |
| Previous Name | NA |
| Gm Offical Target Name | CALCRL |
| Package |
